+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Binge Eating Disorder Market Report and Forecast 2023-2031

  • PDF Icon


  • 160 Pages
  • May 2023
  • Region: Global
  • Expert Market Research
  • ID: 5805735
The global binge eating disorder market value was USD 0.76 billion in 2022, driven by the increasing prevalence of binge eating disorder across the globe. The market size is anticipated to grow at a CAGR of 6.1% during the forecast period of 2023-2031 to achieve a value of USD 1.28 billion by 2031.


Binge eating disorder (BED) is a serious eating disorder characterized by recurring episodes of consuming large amounts of food within a short period of time, accompanied by a feeling of loss of control and significant distress. It is the most common eating disorder in the United States and affects people of all ages and genders. BED can have detrimental effects on physical health, emotional well-being, and overall quality of life.

Key Trends in the Binge Eating Disorder Market

Some key trends involved in the binge eating disorder market are as follows:
  • Growing Awareness and Recognition: There has been a significant increase in awareness and recognition of Binge Eating Disorder in recent years. More healthcare professionals, including doctors, psychologists, and nutritionists, are being trained to identify and diagnose BED. This has led to improved access to appropriate treatment and support for individuals with BED
  • Multidisciplinary Treatment Approaches: The treatment of Binge Eating Disorder has evolved to embrace a multidisciplinary approach. It involves a combination of therapies, including cognitive-behavioral therapy (CBT), interpersonal psychotherapy, and dialectical behavior therapy, along with nutritional counseling and support groups. This comprehensive approach addresses the psychological, emotional, and behavioral aspects of BED
  • Focus on Individualized Treatment: There is a growing emphasis on individualized treatment plans for individuals with BED. Recognizing that each person's experience and needs are unique, healthcare professionals tailor treatment approaches to meet the specific requirements of the individual. This personalized approach improves treatment outcomes and helps individuals develop coping strategies and healthier relationships with food

Binge Eating Disorder Market Segmentations

Market Breakup by Treatment


  • Antidepressant
  • Anticonvulsant
  • Anti-obesity Medication
  • Others


  • Inpatient
  • Outpatient

Market Breakup by Route of Administration

  • Oral
  • Parenteral
  • Others

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada


  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Binge Eating Disorder Market Scenario

The market for Binge Eating Disorder (BED) treatment and support has witnessed significant growth in recent years. The rising prevalence of BED, along with increased awareness and recognition of the disorder, has fueled the demand for effective interventions and services. Healthcare providers, pharmaceutical companies, and technology firms are actively involved in addressing the needs of individuals with BED and offering innovative solutions to improve their quality of life.

The market for BED treatment comprises various stakeholders, including healthcare providers, therapists, pharmaceutical companies, digital health solution providers, and support groups. These stakeholders work together to provide comprehensive treatment approaches that address the complex nature of BED. The market is driven by the growing understanding of the psychological, emotional, and behavioral aspects of the disorder and the need for tailored treatment plans.

The increasing adoption of telehealth and digital solutions has transformed the landscape of BED treatment. Telehealth platforms allow for remote consultations, therapy sessions, and monitoring, making care more accessible and convenient for individuals with BED. Digital health applications and online support communities provide additional resources, self-monitoring tools, and peer support to individuals seeking treatment for BED.

Pharmaceutical companies are also investing in research and development to explore pharmacological interventions for BED. The aim is to develop medications that can effectively reduce binge eating episodes, address underlying psychological factors, and improve overall well-being for individuals with BED.

The market for BED treatment is expected to witness further growth due to the growing recognition of the disorder, increased access to treatment and support, and advancements in technology and pharmaceutical interventions. The focus on personalized treatment plans, multidisciplinary approaches, and ongoing research on innovative therapies will continue to shape the market dynamics and contribute to better outcomes for individuals with BED.

Binge Eating Disorder Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Tonix Pharmaceuticals Holding Corp
  • Takeda Pharmaceutical Company Limited
  • Chronos Therapeutics Limited
  • Pyramid Healthcare Inc
  • Sunovion Pharmaceuticals Inc
  • H. Lundbeck A/S
  • Orexigen Therapeutics, Inc
  • Novo Nordisk A/S
  • Eli Lily and Company
  • Jazz Pharmaceuticals Inc

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Binge Eating Disorder Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Binge Eating Disorder Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Binge Eating Disorder Epidemiology (2016-2031)
5.3 Europe Binge Eating Disorder Epidemiology (2016-2031)
5.4 Asia-Pacific Binge Eating Disorder Epidemiology (2016-2031)
5.5 Latin America Binge Eating Disorder Epidemiology (2016-2031)
5.6 Middle East & Africa Binge Eating Disorder Epidemiology (2016-2031)
6 Global Binge Eating Disorder Market Overview
6.1 Global Binge Eating Disorder Market Historical Value (2016-2022)
6.2 Global Binge Eating Disorder Market Forecast Value (2023-2031)
7 Global Binge Eating Disorder Market Landscape
7.1 Global Binge Eating Disorder Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Binge Eating Disorder Product Landscape
7.2.1 Analysis by Treatment
7.2.2 Analysis by Route of Administration
7.2.3 Analysis by Distribution Channel
8 Binge Eating Disorder Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Binge Eating Disorder Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Binge Eating Disorder Market Segmentation
11.1 Global Binge Eating Disorder Market by Treatment
11.1.1 Market Overview
11.1.1 Medication Antidepressant Anticonvulsant Anti-obesity Medication Others
11.1.2 Therapies
11.2 Global Binge Eating Disorder Market by Services
11.2.1 Inpatient
11.2.2 Outpatient
11.3 Global Binge Eating Disorder Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Parenteral
11.3.4 Others
11.4 Global Binge Eating Disorder Market by Distribution Channel
11.4.1 Market Overview
11.4.2 Hospital Pharmacy
11.4.3 Retail Pharmacy
11.4.4 Online Pharmacy
11.4.5 Others
11.5 Global Binge Eating Disorder Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.3 Europe
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Binge Eating Disorder Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Binge Eating Disorder Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Binge Eating Disorder Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Binge Eating Disorder Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Binge Eating Disorder Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Regulatory Framework
22.1 Regulatory Overview
22.1.1 US FDA
22.1.2 EU EMA
22.1.5 Others
23 Supplier Landscape
23.1 Tonix Pharmaceuticals Holding Corp.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Takeda Pharmaceutical Company Limited
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Chronos Therapeutics Limited
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Pyramid Healthcare Inc.
23.4.1 Financial Analysis
23.4.2 Financial Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Sunovion Pharmaceuticals Inc.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 H. Lundbeck A/S
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Orexigen Therapeutics, Inc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Novo Nordisk A/S
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Eli Lily and Company
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Jazz Pharmaceuticals Inc.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
24 Global Binge Eating Disorder Market - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Companies Mentioned

  • Tonix Pharmaceuticals Holding Corp.
  • Takeda Pharmaceutical Company Limited
  • Chronos Therapeutics Limited
  • Pyramid Healthcare Inc.
  • Sunovion Pharmaceuticals Inc.
  • H. Lundbeck A/S
  • Orexigen Therapeutics Inc.
  • Novo Nordisk A/S
  • Eli Lily and Company
  • Jazz Pharmaceuticals Inc.



Table Information